
By: Andrew Ross Sorkin, Jason Karaian, Vivian Giang, Stephen Gandel, Lauren Hirsch, Ephrat Livni and Anna Schaverien (NY Times Dealbook)
Airlines and antitrust
A fight is brewing over the future of the budget carrier Spirit Airlines that could give rise to a credible competitor to the industry’s “Big Four.”
In February, Frontier Airlines and Spirit announced plans to merge, promising to create a national budget airline that would help keep fares low. But this week, JetBlue Airways swooped in with a $3.6 billion all-cash bid for Spirit, a significantly higher offer than Frontier’s cash-and-stock deal. Late yesterday, Spirit said it would start talks with JetBlue to assess the merits of its bid.
Either offer will attract close regulatory scrutiny. They will also test the way that trustbusters review deals, as officials increasingly consider more than just market share, The Times’s Niraj Chokshi and DealBook’s Lauren Hirsch report.
The deal is the latest example of a bidding war in which antitrust scrutiny plays a leading role. Frontier’s bid for Spirit is lower than JetBlue’s, but Frontier argues that its deal offers more regulatory certainty, given that JetBlue is bigger and focuses on higher-priced fares. This is a sign of the times — see the fight over the Kansas City Southern railroad — as policymakers focus on the impact of deals on economic inequality, inflation and wages.
“Both deals present a new challenge to antitrust agencies,” said Paul Denis, who represented US Airways in its merger with American Airlines, and previously worked at the Justice Department. A review of any deal involving Spirit would explore whether there is a “unique rivalry” among lower-cost carriers. After waves of consolidation among larger legacy airlines, American, Delta, United and Southwest have a combined 66 percent share of the U.S. market. Frontier-Spirit would control 8 percent, while JetBlue-Spirit would account for 10 percent…
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas